Prenetics Global Ltd. has issued a correction to its financial statements for the six months ended June 30, 2025, to restate comparative figures following the divestment of its 70% equity interest in ACT Genomics Holdings Company Limited. The results of ACT Genomics have been re-presented as a discontinued operation in the restated financial statements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001876431-25-000016), on October 21, 2025, and is solely responsible for the information contained therein.